NRSN•prnewswire•
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
Summary
CAMBRIDGE, Mass., Dec. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that following a productive discussion with Health...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 4, 2025 by prnewswire